Genomic Vision Announces the Issuance of the 1st Tranche of Convertible Notes With Warrants (OCABSA) for €2 Million, as Part of the Financing Line Concluded With Winance for a Maximum Amount of €30 Million
06 Setembro 2022 - 1:00PM
Business Wire
Regulatory News:
Genomic Vision (the “Company” - FR0011799907 – GV)
(Paris:GV), a biotechnology company that develops tools and
services dedicated to the analysis and control of changes in the
genome, today announces the issuance of the first tranche of
convertible notes with equity warrants attached (OCABSA) for a
total net amount of €1.920 million.
In a press release dated May 20, 2022, the Company announced the
signing of a contract with Winance on April 11, 2022 as modified on
May 18, 2022 to setting up a financing line by issuing convertible
bonds (the “OC”) into ordinary shares to each of which will
be attached a share subscription warrant (the “BSA” and
together with the shares to which they are attached the
“ABSA” and with the OC the “OCABSA”), for a maximum
total amount of €28.8 million (€30 million nominal value). The
extraordinary shareholders meeting of the Company held on May 23,
2022 approved the implementation of this financing line.
Terms of the operation By using the delegation granted by
the extraordinary shareholders meeting, Genomic Vision’s Executive
Board decided, on June 10, 2022, to issue 2,000 OCABSA with a
nominal value of €2 million for the benefit of Winance (the
“Investor”) for a total net amount of €1.920 million, as well as
525,000 bonds convertible into shares delivered in payment of the
first quarter of the Investor's commitment fee. The OCABSA were
paid up in several installments, the last part of which was paid on
August 29, 2022.
The gross proceeds of the transaction will therefore be €2
million and the net proceeds €1.920 million.
The main terms of this financing programme structured in 15
tranches of OCABSA totalling €28.8 million are described in the
prospectus approved by the Autorité des marchés financiers (AMF) on
May 20, 2022 under no. 22-170, consisting of the universal
registration document filed on April 14, 2022 under number
D.22-0293, the amendment to the universal registration document
filed on May 20, 2022 under number D.22-0293-A01, a transaction
note and a summary, available at the Company's registered office
(80/84 Rue des Meuniers, 92220 Bagneux), on the Company's website
(www.genomicvision.com) and on that of the AMF
(www.amf-france.org).
***
Upcoming financial publications
- H1 2022 results: Thursday, September 29, 2022 (after
market)
- Q3 2022 revenue: Thursday, October 27, 2022 (after market)
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company developing products
and services dedicated to the analysis (structural and functional)
of genome modifications as well as to the quality and safety
control of these modifications, in particular in genome editing
technologies and biomanufacturing processes. Genomic Vision
proprietary tools, based on DNA combing technology and artificial
intelligence, provide robust quantitative measurements needed to
high confidence characterization of DNA alteration in the genome.
These tools are mainly used for monitoring DNA replication in
cancerous cell, for early cancer detection and the diagnosis of
genetic diseases. Genomic Vision, based near Paris in Bagneux, is a
public listed company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
***
Member of the CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 14, 2022 under
reference number R.22-0293, as updated by the amendment filed with
the AMF on May 20, 2022, under number D.22-0293-A01, available on
the web site of Genomic Vision (www.genomicvision.com) and to the
development of economic conditions, financial markets and the
markets in which Genomic Vision operates. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Genomic Vision or not currently considered
material by Genomic Vision. The occurrence of all or part of such
risks could cause actual results, financial conditions, performance
or achievements of Genomic Vision to be materially different from
such forward-looking statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220906005796/en/
Genomic Vision Aaron Bensimon CEO Tel.: +33 1 49 08 07 51
investisseurs@genomicvision.com Ulysse Communication
Press Relations Bruno Arabian Tel.: +33 1 42 68 29 70
barabian@ulysse-communication.com NewCap Investor
Relations & Strategic Communications Tel.: +33 1 44
71 94 94 gv@newcap.eu
Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Goldfield (AMEX:GV)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024